Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment

Blood (2016) 128 (22): 347.

https://doi.org/10.1182/blood.V128.22.347.347

Published: 2016

Journal Articles

A Phase I-II Study of the Efficacy and Safety of Lenalidomide (LEN) Combined to Azacitidine (AZA) in Higher Risk MDS and AML with Del 5q - a Study By the Groupe Francophone Des Myelodysplasies (GFM)

Lionel Ades, MD PhD, Christian Récher, MDPhD, Julie Lejeune, Aspasia Stamatoullas, MD, Marie Sebert, MD, Jacques Delaunay, MD, Benedicte Samey, Krimo Bouabdallah, MD, Thorsten Braun, MD PhD, Norbert Vey, Sophie Park, MD PhD, Benoit de Renzis, Sylvie Chevret, Pierre Fenaux, MD PhD

Blood (2015) 126 (23): 2892.

https://doi.org/10.1182/blood.V126.23.2892.2892

Published: 2015

Journal Articles

A Phase II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (AZA) in Intermediate-2 and High Risk MDS Patients: A Study By the Groupe Francophone Des Myelodysplasies (GFM)

Lionel Ades, MD PhD, Agnes Guerci-Bresler, MD, Pascale Cony-Makhoul, MD, Laurence Legros, MD, Marie Sebert, MD, Thorsten Braun, MD PhD, Jacques Delaunay, MD, Benedicte Samey, Kristell Desseaux, Sylvie Chevret, Pierre Fenaux, MD PhD

Blood (2015) 126 (23): 2869.

https://doi.org/10.1182/blood.V126.23.2869.2869

Published: 2015

Journal Articles

Azacitidine (AZA) Combined with Idarubicin in Higher Risk MDS - Results of a Phase I/II Study By the Groupe Francophone Des Myelodysplasies (GFM)

Marie Sebert, MD, Aspasia Stamatoullas, MD, Thorsten Braun, MD PhD, Jacques Delaunay, MD, Benoît de Renzis, Ramzi Jeddi, MD, Balkis Meddeb, Mathilde Hunault Berger, Benedicte Samey, Fatiha Chermat, Sylvie Chevret, Cendrine Chaffaut, Pierre Fenaux, MD PhD, Lionel Ades, MD PhD

Blood (2015) 126 (23): 2884.

https://doi.org/10.1182/blood.V126.23.2884.2884

Published: 2015

Journal Articles

A Phase II Study Of The Efficacy and Safety Of An Intensified Schedule Of Azacitidine (AZA) In Intermediate-2 and High Risk MDS Patients

Lionel Ades, Agnès Guerci-Bresler, MD, PhD, Pascale Cony Makhoul, Laurence Legros, MD, PhD, Jacques Delaunay, MD, Christian Recher, MD PhD, Kristell Desseaux, Benedicte Samey, Sylvie Chevret, Pierre Fenaux, MD, PhD

Blood (2013) 122 (21): 1513.

https://doi.org/10.1182/blood.V122.21.1513.1513

Published: 2013

Journal Articles

A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q – A Study By The Groupe Francophone Des Myelodysplasies (GFM)

Lionel Ades, Christian Recher, MD PhD, Aspasia Stamatoullas, Krimo Bouabdallah, MD, Jacques Delaunay, MD, Francois Dreyfus, MD, Norbert Vey, MD PhD, Benoit de Renzis, Emmanuel Raffoux, Françoise Isnard, MD, Benedicte Samey, Cendrine Chaffaut, Sylvie Chevret, Pierre Fenaux, MD, PhD

Blood (2013) 122 (21): 2750.

https://doi.org/10.1182/blood.V122.21.2750.2750

Published: 2013

Journal Articles

Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM)

Lionel Ades, Thomas Prebet, MD PhD, Aspasia Stamatoullas, Christian Recher, MD PhD, Romain Guieze, MD, Emmanuel Raffoux, Krimo Bouabdallah, MD, Mathilde Hunault, Eric Wattel, Laure Stalnikiewicz, MD, Andrea Toma, Herve Dombret, MD, PhD, Norbert Vey, MD PhD, Claude Gardin, MD, Benedicte Samey, Sylvie Chevret, Pierre Fenaux, MD, PhD

Blood (2013) 122 (21): 620.

https://doi.org/10.1182/blood.V122.21.620.620

Published: 2013

Journal Articles

Azacitidine (AZA) Combined with Idarubicin in Untreated Patients with High Risk MDS – Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies

Lionel Ades, MD, PhD, Benoit de Renzis, Ramzi Jeddi, MD, Jacques Delaunay, MD, Thorsten Braun, Mathilde Hunault Berger, MD, PhD, Aspasia Stamatoullas, Laurence Sanhes, MD, Benedicte Samey, Fatiha Chermat, Baklis Meddeb, Pierre Fenaux, MD, PhD

Blood (2012) 120 (21): 1720.

https://doi.org/10.1182/blood.V120.21.1720.1720

Published: 2012

Journal Articles

Allogeneic Stem Cell Transplantation (allo-SCT) for Isolated and Leukemic Myeloid Sarcoma (GS): a Survey on Behalf of the Acute Leukemia Working Party (ALWP) of EBMT.

Patrice Chevallier, MD, Myriam Labopin, MD, Jan J. Cornelissen, MD, PhD, Gérard Socié, Per T. Ljungman, MD, PhD, Bruno Lioure, Herve Tilly, MD, Alois Gratwohl, MD, Noel Milpied, MD, Ibrahim Yakoub-Agha, MD, PhD, Liisa Volin, Jean-Paul Vernant, Jacques-Olivier Bay, MD, PhD, Mauricette Michallet, Agnès Buzyn, MD, PhD, Benedicte Samey, Mohamad Mohty, Vanderson Rocha

Blood (2010) 116 (21): 4558.

https://doi.org/10.1182/blood.V116.21.4558.4558

Published: 2010

Journal Articles

Higher Incidence of Relapse with Peripheral Blood Rather Than Marrow as a Source of Stem Cells in Adults with Acute Myelocytic Leukemia, but Not in Adults with Acute Lymphocytic Leukemia Autografted during the First Remission

Norbert C Gorin, Myriam Labopin, Emmanuelle Polge, Benedicte Samey, Vanderson Rocha

Blood (2008) 112 (11): 3311.

https://doi.org/10.1182/blood.V112.11.3311.3311

Published: 2008

Journal Articles

Intravenous Busulfan-Based Conditioning Prior to Allogeneic Stem Cell Transplantation in Adults Patients with AML - An ALWP-EBMT Survey.

Arnon Nagler, MD, Myriam Labopin, MD, Avichai Shimoni, MD, Donald Bunjes, MD, Pedro Pimentel, MD, Gerard Socie, MD, Karim Boudjedir, MD, Axel R. Zander, MD, A. Torres Gomez, MD, Michele Baccarini, MD, Hakan Goker, MD, Athanasios Fassas, MD, Chantal Kenzey, Benedicte Samey, Zouabi Hamadi, MD, Vanderson Rocha, MD

Blood (2007) 110 (11): 1995.

https://doi.org/10.1182/blood.V110.11.1995.1995

Published: 2007

NARROW

Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment

A Phase I-II Study of the Efficacy and Safety of Lenalidomide (LEN) Combined to Azacitidine (AZA) in Higher Risk MDS and AML with Del 5q - a Study By the Groupe Francophone Des Myelodysplasies (GFM)

A Phase II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (AZA) in Intermediate-2 and High Risk MDS Patients: A Study By the Groupe Francophone Des Myelodysplasies (GFM)

Azacitidine (AZA) Combined with Idarubicin in Higher Risk MDS - Results of a Phase I/II Study By the Groupe Francophone Des Myelodysplasies (GFM)

A Phase II Study Of The Efficacy and Safety Of An Intensified Schedule Of Azacitidine (AZA) In Intermediate-2 and High Risk MDS Patients

A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q – A Study By The Groupe Francophone Des Myelodysplasies (GFM)

Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM)

Azacitidine (AZA) Combined with Idarubicin in Untreated Patients with High Risk MDS – Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies

Allogeneic Stem Cell Transplantation (allo-SCT) for Isolated and Leukemic Myeloid Sarcoma (GS): a Survey on Behalf of the Acute Leukemia Working Party (ALWP) of EBMT.

Higher Incidence of Relapse with Peripheral Blood Rather Than Marrow as a Source of Stem Cells in Adults with Acute Myelocytic Leukemia, but Not in Adults with Acute Lymphocytic Leukemia Autografted during the First Remission

Intravenous Busulfan-Based Conditioning Prior to Allogeneic Stem Cell Transplantation in Adults Patients with AML - An ALWP-EBMT Survey.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only